Donald Mattison

MD, MS, BA

Chief Medical Officer,
Senior Vice-President

  • USA

    Country of Residence

Donald Mattison

Personal Introduction

From my early academic years, the journey through science and medicine seemed inevitable. After obtaining my Bachelors in Chemistry and Mathematics at Augsburg College in Minnesota in 1966, I was off to the Massachusetts Institute of Technology for a Master of Science in Chemistry. My thesis at M.I.T. was entitled: The Design and Construction of an 18 MHz Pulsed Nuclear Magnetic Resonance Spectrometer. A prelude to Magnetic resonance imaging and solid state NMR.

After completing my MS I was drawn to the study of medicine graduating with an MD from the Vagelos College of Physicians and Surgeons at Columbia University, in New York, in spring of 1973. My subsequent clinical training was divided in two with a residency in obstetrics and gynecology at Sloane Hospital for Women at the Columbia Presbyterian Medical Center in New York and a second position as Clinical Associate in Developmental and Reproductive Pharmacology and Toxicology at the Eunice Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland. These two positions focused on clinical practice and research in risk sciences – with attention to pharmacology and toxicology applied to reproductive and developmental toxicology.

In later years, as I moved to different positions, to continue clinical practice, I obtained medical licenses in six U.S. States including New York (), South Carolina (), Maryland, Arkansas, Pennsylvania and Massachusetts. I would also pursue a desire to serve the nation by joining the U.S. Public Health Service, a uniformed service of the Department of Health and Human Services, ultimately, retiring in 2012 with the rank of Captain (O6).
Professionally, I have been honored with appointments such as Dean, Graduate School of Public Health at the University of Pittsburgh, Medical Director of the March of Dimes, and as the Chief, Section on Reproductive Toxicology at the Eunice Shriver National Institutes of Health in Bethesda, Maryland.
I have also had the privilege of engaging in multiple community service opportunities notably as the Director, Board of Directors and Chair of the Education Committee, Foundation for Advanced Education in the Sciences (FAES), National Institutes of Health, Bethesda MD: 2015 – 2020. I also served as a volunteer physician and Associate Medical Director for the Mercy Health Clinic in Gaithersburg, Maryland. Currently, I am a volunteer physician and Chair of the Quality Improvement Committee for Volunteers in Medicine, on Hilton Head Island in South Carolina.

In 2012, I was excited to join Dr. Krewski and Greg Paoli’s team at Risk Sciences International as Senior Vice-President and Chief Medical Officer.

Donald Mattison-1

As with many RSI staff, Dr. Mattison is passionate about sharing his findings and knowledge with the broader scientific community.

Donald Mattison: Current Focus

Dr. Donald Mattison was appointed Chief Medical Officer and Senior Vice President of Risk Sciences International in 2012.

Dr. Mattison also serves as Associate Director of the McLaughlin Centre for Population Health Risk Assessment and as Adjunct Professor at the School of Epidemiology and Public Health at the University of Ottawa.

He is also Medical Advisor to QuarterWatch: Monitoring FDA MedWatch Reports published by the Institute for Safe Medication Practices in Horsham, Pennsylvania and is currently a Senior Research Fellow at the International Prevention Research Institute in Lyon, France.

Dr. Mattison’s current focus of research is in drug safety and efficacy monitoring.

Works and Accomplishments

Professional Certification

  • Fellow, Academy of Toxicological Science, Recertified 2014
  • Certified, General Toxicology, American Board of Toxicology, 1992

Appointments

  • Chief Medical Officer and Senior Vice President: 2012 – present
    Risk Sciences International, Ottawa, Ontario, Canada and Hilton Head Island, South Carolina, USA
  • Associate Director: 2012 – present
    McLaughlin Centre for Population Health Risk Assessment
    University of Ottawa
  • Adjunct Professor: 2017 – present
    School of Epidemiology and Public Health, University of Ottawa
  • Medical Advisor to QuarterWatch: Monitoring FDA MedWatch Reports: 2013 – present
    Institute for Safe Medication Practices, ISMP, Horsham PA
  • Senior Research Fellow: 2014 – present
    International Prevention Research Institute, iPRI, Lyon, France
  • Senior Advisor to the Director of the Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health: 2002 – 2012
    • Chair, Federal Advisory Committee, National Children’s’ Study
    • Chief, Obstetric and Pediatric Pharmacology Branch CRMC
    • Medical Officer, Epidemiology Branch, DESPR, NICHD, NIH
  • Medical Director, March of Dimes: 1998 – 2002
    March of Dimes Birth Defects Foundation, National Office, White Plains, New York
  • Dean, Graduate School of Public Health, University of Pittsburgh: 1990 – 1998
    Professor of Environmental and Occupational Health, Graduate School of Public Health
  • Professor of Obstetrics, Gynecology, and Reproductive Sciences, School of Medicine, Department of Obstetrics, Gynecology, and Reproductive Sciences, University of Pittsburgh, Pittsburgh, Pennsylvania
  • Associate Professor to Professor, University of Arkansas for Medical Sciences: 1984 – 1990
    Department of Obstetrics and Gynecology and Pharmacology, University of Arkansas for Medical Sciences, Little Rock, AR
  • Reserve Medical Officer, US Food and Drug Administration, USPHS: 1984 – 1990
    Director of the Human Risk Assessment Program, National Center for Toxicological Research, FDA, Jefferson, AR
  • Medical Officer and Chief, Section on Reproductive Toxicology, NICHD, NIH: 1978 – 1984
    Pregnancy Research Branch, National Institute of Child Health and Human Development, National Institutes of Health

Academic Biographical Information

Scopus ID 7005724234
Researcher ID; http://www.researcherid.com/rid/L-4661-2013
ORCID ID 0000-0001-5623-0874

Medical Licenses

  • New York (121258, Active)
  • South Carolina (VL32359, Active)
  • Maryland (D0061516, Inactive)
  • Arkansas (N 67, Inactive)
  • Pennsylvania (MD-044789-L, Inactive)
  • Massachusetts (79113, Inactive)

Uniformed Service

U.S. Public Health Service, Captain (O6, Retired 2012)

USPHS Awards

  • Unit Commendation, Billet Transformation (January 2013)
  • Unit Commendation, Readiness (PHS May 2012)
  • Commissioned Corps Training Ribbon (PHS March 2007)
  • Outstanding Unit Citation (PHS January 2007)
  • Global Response Service Award (PHS October 2006)
  • Meritorious Unit Commendation (USN March 2007)
  • Hazardous Duty Award (PHS August 2006)
  • Foreign Duty Award (PHS August 2006)
  • Crisis Response Service Award (PHS January 2006)
  • Achievement Medal (PHS April 2005)
  • Crisis Response Service Award (PHS November 2004)

USPHS Deployments and Training

  • 2009 OFRD Medical Readiness Training, Fort A P Hill, Virginia
  • 2009 IRCT Basic Online Course
  • 2008 Rosebud Indian Health Service, South Dakota, clinical support in obstetrics and gynecology
  • 2006 USNS MERCY Humanitarian Mission Philippines – Operation Enduring Freedom
  • 2005 Hurricane Katrina
  • 2005 Inauguration
  • 2005 National Mall July 4th NPS Support
  • 2004 Florida Hurricanes
  • 2003 Anthrax Response
  • 2003 Mass Vaccination with National Pharmaceutical Stockpile Course

USPHS Volunteer Activity

  • Associate Recruiter, PPAC Communications Committee, Readiness Working Group

Editor

  • The Clinical Utility of Compounded Bioidentical Hormone Therapy. A Review of Safety Effectiveness and Use, Donald R. Mattison, Ruth Parker, Jackson Leigh Miles 2020. https://nap.edu.25791.
  • Manganese Showcase Symposium, Donald R Mattison, Len Levy, Doreen McGough, Editors, Special Issue of NeuroToxicology. 2017. http://dx.doi.org/10.1016/j.neuro.2016.11.004Ut
  • Risk Science in the 21st Century, Tara Barton-Maclaren, Shalu Darshan, Donald R Mattison, Editors, Special Issue of the International Journal of Risk Assessment and Management. 2017, V20, 1/2/3.
    http://www.inderscience.com/info/inarticletoc.php?jcode=ijram&year=2017&vol=20&issue=1/2/3
  • Computational Approaches for Reproductive and Developmental Toxicology, Donald R. Mattison, Editor, CRC Taylor and Francis Press, Published 2015. ISBN-13: 978-1439861073, ISBN-10: 1439861072
  • Clinical Pharmacology During Pregnancy, Donald R. Mattison, Editor, LWW Elsevier, Published December 2012. Academic Press ISBN: 9780123860071
  • Frontiers in Pediatric Clinical Pharmacology, Associate Editor for Perinatal Pharmacology, 2010 – 2012.
  • The Newborn Drug Development Initiative, George Giacoia, Debbie Birenbaum, Hari Sachs, Donald R. Mattison, Pediatrics Supplement Volume 117 March 2006.
  • The Role of Environmental Hazards in Premature Birth: Donald R. Mattison, Samuel Wilson, Christine Coussens, and Dalia Gilbert, Editors, Roundtable on Environmental Health Sciences, Research, and Medicine, National Academies Press, 2003.
  • New Perspectives on the Stubborn Challenge of Preterm Birth, Pediatric and Prenatal Epidemiology, Volume 15, Supplement 2, July 2001.

Editorial Responsibility

  • Waste Incineration and Public Health. Committee on Health Effects of Waste Incineration, National Research Council. National Academy Press, Washington, D.C., 1999.
  • Toward Environmental Justice: Research, Education and Health Policy Needs. Committee on Environmental Justice, Institute of Medicine. National Academy Press, Washington, D.C., 1999.
  • Government/Research Councils Initiative on Risk Assessment and Toxicology, Workshop on Strategies in Relation to Population Sub Groups. Institute for Environment and Health, April 1997.
  • International Program on Chemical Safety, Environmental Health Criteria 184: Diflubenzuron. World Health Organization, 1996.
  • International Program on Chemical Safety, Environmental Health Criteria 183: Chlorothalonil. World Health Organization, 1996.
  • International Program on Chemical Safety, Environmental Health Criteria 178: Methomyl. World Health Organization, 1996.
  • International Program on Chemical Safety, Environmental Health Criteria 177: 1, 2-Dibromoethane, World Health Organization, 1996.

Consultant, Professional Service, and Administrative Responsibility

  • Society of Toxicology, Scientific Program Committee, 2012 – 2016
  • American Society for Pharmacology and Experimental Therapeutics, Chair, Drug Discovery, Development and Regulatory Affairs Section, 2011 – 2015
  • Canadian Institute for Health Research, IDCYH Advisory Board 2007 – 2012
  • Japanese Ministry of Health, Consultation on Pediatric Clinical Trials Research, January 2007
  • European Union, Directorate General for Research, Consultation on pediatric drug development, 2007 – 2010
  • WHO Consultation, Pediatric Essential Medicines and Global research agenda for pediatric drug development, 2007 – 2009
  • WHO Consultation, Global Burden of Foodborne Diseases, Geneva, September 2006
  • WHO Consultation, Biomonitoring of Human Milk for Persistent Organic Pollutants, Geneva, September 2006
  • WHO Consultation, Biomonitoring of Human Milk for Persistent Organic Pollutants, Geneva, June – July 2004
  • Committee on the Evaluation of Children’s Health, Institute of Medicine, National Academy of Sciences. Chair: 2001 – 2002, Member 2002 – 2003
  • Harvard Center for Risk Analysis Scientific Panel on Low-Dose Effects of Bisphenol A. Chair: 2001 – 2002
  • Board of Scientific Counselors, Office of Research and Development, Environmental Protection Agency. Member: 2000 – 2003.
  • Collegiate Commission on Nursing Education. Board: 1999 – 2006; Treasurer: 2003 – 2006
  • Science Advisory Board, US Environmental Protection Agency, Member, 1999- 2003
  • Science Advisory Board, National Toxicology Program, National Institute of Environmental Health Sciences, NIH. Member: 1999 – 2004
  • Science Advisory Board, Agency for Toxic Substances Disease Registry, Centers for Disease Control and Prevention. Member: 1999 – 2003
  • Children’s Environmental Health Protection Advisory Committee, United States Environmental Protection Agency. Member: 1997 – 2003
  • Commission on Life Sciences, National Research Council, National Academy of Sciences. Member: 1995 – 2000
  • Committee on Environmental Justice, Board on Health Policy, Institute of Medicine. Member: 1995 – 1999
  • Council for Education in Public Health. Representing the Association of Schools of Public Health. Counselor: 1995 – 1998
  • Committee on Health Effects of Waste Incineration, Board on Environmental Studies and Toxicology, National Research Council. Chair and Member: 1994 – 2000
  • Board on Environmental Studies and Toxicology, National Research Council. Member/Vice Chairman: 1987 – 1993/1997 – 2000
  • Board of Directors, Pennsylvania Public Health Association. Member: 1993 – 1996
  • Board on Health Promotion and Disease Prevention, Institute of Medicine, National Academy of Sciences. Member/Chairman: 1993 – 2000/1994 – 2000
  • Scientific Advisory Board Hawaii Heptachlor Education and Research Foundation. Member/Chairman: 1987 – 2002/1999 – 2002

Member of Professional Organizations

  • American Association of Advancement of Science (1991-present)
  • American Society of Pharmacology and Experimental Therapeutics (2000-present)
  • Teratology Society (1990-present)
  • American Public Health Association (1990-present)
  • American College of Toxicology (1985-present)
  • Society for Gynecologic Investigation (1985-present)
  • Society of Toxicology (1985-present)
  • New York Academy of Science (1980-present)
  • New York Academy of Medicine (1980-present)
  • Drug Information Association (2010-present)

Awards and Honors

  • Elected Foreign Fellow, Royal Society of Medicine, London, 2009
  • Distinguished Alumni, Augsburg College, 2005
  • Leveraging/Collaboration Award, Food and Drug Administration, 2005
  • Elected Member, National Academy of Medicine (previously Institute of Medicine), 2000
  • Elected Member, New York Academy of Medicine, 1999
  • Elected Fellow, American Association for the Advancement of Science, 1997
  • Elected Member, Delta Omega, Public Health Honor Society, 1991

Graduate Courses Organized and Taught

  • Risk Based Decision-Making. Course organized and taught by members and affiliates of Risk Sciences International during 2015, 2016, 2017 in Ottawa, ON.
  • Pharmacovigilance Working Group Research Seminar, McLaughlin Centre for Population Health Risk Assessment. Research seminar co-organized with Dan Krewski during the 2012-2013, 2013-2014, 2014-2015, 2015-2016 academic years at the University of Ottawa for approximately 30 participants (graduate students, fellows, and faculty).
  • Pharmacovigilance Seminar, South Carolina College of Pharmacy. Seminar course organized and taught during the 2012-2013 academic year at the invitation and sponsorship of the Provost of the University of South Carolina for approximately 30 students.
  • Summer Institute in Obstetric and Pediatric Pharmacology, This was a unique course developed and implemented in collaboration with the National Institutes of Health (NIH), and the Canadian Institute for Health Research (CIHR) and was presented annually with CIHR funding from 2005 through 2015 to approximately 20 US, Canadian and international students each year.
  • European Course on the Evaluation of Medicinal Products in Children, University of Paris Descartes, University Claude Bernard Lyon, European Society for Developmental Perinatal and Pediatric Pharmacology. Course developed and taught annually from 2002- 2013 to approximately 50 international students each year. Successful completion of the course leads to a certificate.
  • Overview of Endocrine, Reproductive and Developmental Toxicology, Department of Environmental Health, Mailman School of Public Health, Columbia University (this is a single 3 hour survey lecture as part of the core course on toxicology taught each spring from 2002 to 2008)
  • Introduction to Endocrine, Reproductive and Developmental Toxicology, Department of Environmental Health, Mailman School of Public Health, Columbia University (Spring Term 2002, 10 students; Summer 2003, 15 students)
  • Introduction to Risk Analysis (EOH 2180), Department of Environmental and Occupational Health, Graduate School of Public Health, University of Pittsburgh (Summer 1992, 7 students; Summer 1993, 13 students; Summer 1994, 23 students; Summer 1995, 16 students; Summer 1997, 10 students).
  • Risk Assessment Practicum (EOH 2181), Department of Environmental and Occupational Health, Graduate School of Public Health, University of Pittsburgh (Summer 1994, 13 students; Summer 1995, 10 students; Summer 1997, 5 students).
  • Politics of Public Health in Pennsylvania (PUBHLT 2003), Department of Health Services Administration, Graduate School of Public Health, University of Pittsburgh (Fall 1994, 4 students; Fall 1996, 3 students).
  • Federal Politics of Public Health (HSADM2205), Department of Health Services Administration, Graduate School of Public Health, University of Pittsburgh (Spring 1995, 2 students).
  • An Integrative Course on Violence (PUBHLT 2001), Graduate School of Public Health, University of Pittsburgh (Spring 1996, 3 students; Spring 1997, 7 students).

Additional References

Publications
NCBI Bibliography

Dr. Donald Mattison has published nearly 400 peer-reviewed papers throughout his career. Below is a small sample selected by Dr. Mattison.

  1. Mattison D, Gravel C, Krewski D, Azoulay L, Hicks B, Douros A. Direct oral anticoagulants and oesophageal disorders: a pharmacovigilance analysis. Eur J Clin Pharmacol. 2020;76(7):1045-7. Epub 2020/05/08. doi: 10.1007/s00228-020-02877-1. PubMed PMID: 32377758.
  2. Loukotkova L, Basavarajappa M, Lumen A, Roberts R, Mattison D, Morris SM, Fisher J, Beland FA, Gamboa da Costa G. Pharmacokinetics of oseltamivir phosphate and oseltamivir carboxylate in non-pregnant and pregnant rhesus monkeys. Regul Toxicol Pharmacol. 2020;112:104569. Epub 2020/01/14. doi: 10.1016/j.yrtph.2019.104569. PubMed PMID: 31927005.
  3. Farhat N, Birkett N, Haddad N, Fortin Y, Momoli F, Wen SW, Wielgosz A, McNair DS, Mattison DR, Krewski D. Risk of Adverse Cardiovascular Events Following a Myocardial Infarction in Patients Receiving Combined Clopidogrel and Proton Pump Inhibitor Treatment: A Nested Case-Control Study. Drugs Real World Outcomes. 2020;7(3):191-203. Epub 2020/07/04. doi: 10.1007/s40801-020-00204-9. PubMed PMID: 32617885; PMCID: PMC7392938.
  4. Moore TJ, Mattison DR. Assessment of Patterns of Potentially Unsafe Use of Zolpidem. JAMA internal medicine. 2018;178(9):1275-7. Epub 2018/07/18. doi: 10.1001/jamainternmed.2018.3031. PubMed PMID: 30014137; PMCID: PMC6583219.
  5. Davidson MA, Mattison DR, Azoulay L, Krewski D. Thiazolidinedione drugs in the treatment of type 2 diabetes mellitus: past, present and future. Crit Rev Toxicol. 2018;48(1):52-108. Epub 2017/08/18. doi: 10.1080/10408444.2017.1351420. PubMed PMID: 28816105.
  6. Bjerre LM, Parlow S, de Launay D, Hogel M, Black CD, Mattison DR, Grimshaw JM, Watson MC. Comparative, cross-sectional study of the format, content and timing of medication safety letters issued in Canada, the USA and the UK. BMJ Open. 2018;8(10):e020150. Epub 2018/10/10. doi: 10.1136/bmjopen-2017-020150. PubMed PMID: 30297342; PMCID: PMC6194396.
  7. Yannick F, Crispo JAG, Cohen D, Dahrouge S, McNair D, Mattison D, Krewski D. An exposure-response relationship between multimorbidity and motor-vehicle accidents. Journal of Transport & Health. 2017;4:140-51.
  8. Ramoju SP, Mattison DR, Milton B, McGough D, Shilnikova N, Clewell HJ, Yoon M, Taylor MD, Krewski D, Andersen ME. The application of PBPK models in estimating human brain tissue manganese concentrations. Neurotoxicology. 2017;58:226-37. doi: 10.1016/j.neuro.2016.12.001. PubMed PMID: 27989617.
  9. Moore TJ, Mattison DR. Adult Utilization of Psychiatric Drugs and Differences by Sex, Age, and Race. JAMA internal medicine. 2017;177(2):274-5. doi: 10.1001/jamainternmed.2016.7507. PubMed PMID: 27942726.
  10. Milton B, Krewski D, Mattison DR, Karyakina NA, Ramoju S, Shilnikova N, Birkett N, Farrell PJ, McGough D. Modeling U-shaped dose-response curves for manganese using categorical regression. Neurotoxicology. 2017;58:217-25. doi: 10.1016/j.neuro.2016.10.001. PubMed PMID: 27720796.
  11. Mattison DR, Milton B, Krewski D, Levy L, Dorman DC, Aggett PJ, Roels HA, Andersen ME, Karyakina NA, Shilnikova N, Ramoju S, McGough D. Severity scoring of manganese health effects for categorical regression. Neurotoxicology. 2017;58:203-16. doi: 10.1016/j.neuro.2016.09.001. PubMed PMID: 27637608.
  12. Gurusankar R, Yenugadhati N, Krishnan K, Hays SM, Haines D, Zidek A, Kuchta S, Kinniburgh D, Gabos S, Mattison DR, Krewski D. The Role of Human Biological Monitoring (HBM) in Health Risk Assessment. International Journal of Risk Assessment and Management. 2017;20(1/2/3).
  13. Barton-MacLaren TS, Darshan S, Mattison DR. Risk Science in the 21st Century. International Journal of Risk Assessment and Management 2017;20(1/2/3).
  14. Mattison DR. Computational methods for reproductive and developmental toxicology. Boca Raton: CRC Press, Taylor & Francis Group; 2016. xiv, 327 pages p.
  15. Koren G, Hankins GD, Clark S, Caritis SN, Miodovnik M, Umans JG, Mattison DR. Effectiveness of doxylamine-pyridoxine for morning sickness. Am J Obstet Gynecol. 2016;214(5):664-6. doi: 10.1016/j.ajog.2016.01.186. PubMed PMID: 26844757.
  16. Johnson KA, Sjaarda LA, Mumford SL, Garbose RA, Schliep KC, Mattison D, Perkins NJ, Wactawski-Wende J, Schisterman EF. Patterns and prevalence of medication use across the menstrual cycle among healthy, reproductive aged women. Pharmacoepidemiol Drug Saf. 2016;25(6):618-27. doi: 10.1002/pds.3993. PubMed PMID: 26954695; PMCID: PMC4933290.
  17. Tully I, Draper ES, Lamming CR, Mattison D, Thomas C, Martland T, Appleton R. Admissions to paediatric intensive care units (PICU) with refractory convulsive status epilepticus (RCSE): A two-year multi-centre study. Seizure-European Journal of Epilepsy. 2015;29:153-61. doi: 10.1016/j.seizure.2015.04.002. PubMed PMID: WOS:000357767800025.
  18. Matyas RA, Mumford SL, Schliep KC, Ahrens KA, Sjaarda LA, Perkins NJ, Filiberto AC, Mattison D, Zarek SM, Wactawski-Wende J, Schisterman EF. Effects of over-the-counter analgesic use on reproductive hormones and ovulation in healthy, premenopausal women. Hum Reprod. 2015;30(7):1714-23. doi: 10.1093/humrep/dev099. PubMed PMID: 25954035; PMCID: PMC4472321.
  19. LaKind JS, Goodman M, Makris SL, Mattison DR. Improving Concordance in Environmental Epidemiology: A Three-Part Proposal. Journal of toxicology and environmental health Part B, Critical reviews. 2015;18(2):105-20. doi: 10.1080/10937404.2015.1051612. PubMed PMID: 26158301; PMCID: PMC4733943.
  20. Hamel S, McNair DS, Birkett NJ, Mattison DR, Krantis A, Krewski D. Off-label use of cancer therapies in women diagnosed with breast cancer in the United States. Springerplus. 2015;4:209. doi: 10.1186/s40064-015-0981-z. PubMed PMID: 25977897; PMCID: PMC4422830.
  21. Yang X, Morris SM, Gearhart JM, Ruark CD, Paule MG, Slikker W, Jr., Mattison DR, Vitiello B, Twaddle NC, Doerge DR, Young JF, Fisher JW. Development of a physiologically based model to describe the pharmacokinetics of methylphenidate in juvenile and adult humans and nonhuman primates. PloS one. 2014;9(9):e106101. doi: 10.1371/journal.pone.0106101. PubMed PMID: 25184666; PMCID: PMC4153582.
  22. Xie RH, Guo Y, Krewski D, Mattison D, Walker MC, Nerenberg K, Wen SW. Association between labetalol use for hypertension in pregnancy and adverse infant outcomes. Eur J Obstet Gynecol Reprod Biol. 2014;175:124-8. doi: 10.1016/j.ejogrb.2014.01.019. PubMed PMID: 24502872.
  23. Xie RH, Guo Y, Krewski D, Mattison D, Walker MC, Nerenberg K, Wen SW. Beta-blockers increase the risk of being born small for gestational age or of being institutionalised during infancy. BJOG : an international journal of obstetrics and gynaecology. 2014;121(9):1090-6. doi: 10.1111/1471-0528.12678. PubMed PMID: 24628701.
  24. Williams D, Basavarajappa MS, Rasmussen SA, Morris S, Mattison D, Animal Models of Pregnancy Working G. Highlights from the United States Food and Drug Administration’s public workshop on the development of animal models of pregnancy to address medical countermeasures in an “at-risk” population of pregnant women: Influenza as a case study. Birth defects research Part A, Clinical and molecular teratology. 2014;100(10):806-10. doi: 10.1002/bdra.23319. PubMed PMID: 25296888.
  25. Moore TJ, Glenmullen J, Mattison DR. Reports of pathological gambling, hypersexuality, and compulsive shopping associated with dopamine receptor agonist drugs. JAMA internal medicine. 2014;174(12):1930-3. doi: 10.1001/jamainternmed.2014.5262. PubMed PMID: 25329919.
  26. Moore TJ, Cohen MR, Mattison DR. Dabigatran, bleeding, and the regulators. Bmj. 2014;349:g4517. doi: 10.1136/bmj.g4517. PubMed PMID: 25056265.
  27. Mattison DR, Karyakina N, Goodman M, LaKind JS. Pharmaco- and toxicokinetics of selected exogenous and endogenous estrogens: a review of the data and identification of knowledge gaps. Crit Rev Toxicol. 2014;44(8):696-724. doi: 10.3109/10408444.2014.930813. PubMed PMID: 25099693.
  28. Lakind JS, Goodman M, Mattison DR. Bisphenol A and indicators of obesity, glucose metabolism/type 2 diabetes and cardiovascular disease: a systematic review of epidemiologic research. Crit Rev Toxicol. 2014;44(2):121-50. doi: 10.3109/10408444.2013.860075. PubMed PMID: 24392816.
  29. Goodman M, Lakind JS, Mattison DR. Do phthalates act as obesogens in humans? A systematic review of the epidemiological literature. Crit Rev Toxicol. 2014;44(2):151-75. doi: 10.3109/10408444.2013.860076. PubMed PMID: 24417397.
  30. Goodman M, LaKind JS, Fagliano JA, Lash TL, Wiemels JL, Winn DM, Patel C, Van Eenwyk J, Kohler BA, Schisterman EF, Albert P, Mattison DR. Cancer cluster investigations: review of the past and proposals for the future. Int J Environ Res Public Health. 2014;11(2):1479-99. doi: 10.3390/ijerph110201479. PubMed PMID: 24477211; PMCID: PMC3945549.

Case studies associated with Donald Mattison

Alysena Recall

The review involved an analysis of the events and processes that led to public criticism of Health Canada’s handling of the drug company’s recall of a contraceptive drug due to packaging errors.  The evaluation consisted of several components. First, a review and analysis were conducted of the regulatory and procedural basis of the department’s roles…

Read More

Donald Mattison: Extra-curricular / Community Service

Don’s favorite pass-time is fly-fishing and fly-tying, both of which he taught. Among his other extra-curricular and volunteering commitments, Don has served with the following organizations.

  • Trout Unlimited Conservation and Fly-Fishing Camp: 2006 – 2012. (Tri-State region, Maryland/DC, Virginia and West Virginia) – Volunteer camp physician and member of the camp board and fly fishing and tying faculty.
  • Director, Board of Directors and Chair of the Education Committee, Foundation for Advanced Education in the Sciences (FAES), National Institutes of Health, Bethesda MD: 2015 – 2020. The FAES provides education, social and cultural activities for staff, fellows and employees of the National Institutes of Health. The Board of directors provides oversight for FAES activities and the Education Committee provides oversight to the FAES Board and staff on education activity.
  • Mercy Health Clinic, Gaithersburg MD: 2003 – 2012. Volunteer physician and Associate Medical Director for a primary care community health clinic providing free outpatient medical care, pharmaceuticals and education to uninsured residents of the Montgomery County, MD community.
  • Volunteers in Medicine, Hilton Head Island, South Carolina: 2016 – Present. Volunteer physician and Chair of the Quality Improvement Committee for a multispecialty community health clinic providing free outpatient medical and surgical care, wellness, pharmaceuticals, and imaging for children and adults living in Hilton Head and Dufuskie Islands.
Please enter your name.
Please enter a subject.
Please enter a message.
Please check the captcha to verify you are not a robot.
  • 0%

    99% of our added value is our staff.

RSIepidemiologiststoxicologistsmedical doctorsengineersprogrammerssoftware engineerseditorstranslatorscampaignerscommunicatorsperception analystspolicy expertsregulatory advisorschemistsbiologistsclimate expertsurban expertspublic health specialistsmathematicianstrainers

Martin LeBlanc

Mr. Martin LeBlanc is responsible for growing RSI’s book of business, supporting all activities to this end. His line is always open to assist clients old and new. He strives to understand and provide a client’s unique need on a project, having done so for many government and private clients across the health, nuclear, power generation, aerospace, manufacturing, transportation and national defence sectors.

Full Bio...

Hong Duan

Since joining RSI’s technical team in 2011, Hong has focused on developing risk-based database-driven web projects. Her extensive knowledge and experience, has helped RSI to develop high quality software for multiple clients including the Public Health Agency of Canada, the U.S. Food and Drug Administration, the Food and Agriculture Organization of the United Nations based in Rome, and the World Health Organization based in Geneva.

Full Bio...

Franco Momoli

Dr. Momoli is the acting Practice Lead for Chemical and Product Safety at Risk Sciences International, as well as an adjunct professor in the School of Epidemiology and Public Health at the University of Ottawa.

Full Bio...

Todd Ruthman

Todd Ruthman’s current focus is on tools that help regulators visualize and understand the public risk burden within their mandates to help inform risk-based decisions. Mr. Ruthman provides design, management, modelling, coding, and database development expertise for these tools. Mr. Ruthman also manages the RSI development group enhancing previously released tools…

Full Bio...

Emma Hartnett

Dr. Hartnett currently works on the development of risk-based decision-making processes and tools to support public risk assessment. Current focus includes: working with the Canadian Food Inspection Agency exploring methodologies to support risk-based monitoring of contaminants in food; working with Transport Canada to develop guidelines and methodologies to support risk-based decisions related to public risks from the transportation system; working with the U.S. Food and Drug Administration on continuing expansions and improvements to the FDA-iRISK tool.

Full Bio...

Daniel Krewski

Dr. Krewski currently serves as Chief Risk Scientist and CEO of Risk Sciences International, a Canadian company founded in 2006 in partnership with the University of Ottawa. He also holds academic appointments as Professor in the School of Epidemiology and Public Health and Scientific Director of the McLaughlin Centre for Population Health Risk Assessment in the Faculty of Medicine at the University of Ottawa.

Full Bio...

Cemil ‘Jim’ Alyanak

Now serving as RSI’s Vice-President Communications and Strategic Initiatives, for years Cemil has provided organizations with guidance designed to transmit mission-critical messages. An anti-tobacco campaign is not about promoting a strategy, it’s about saving lives. Get the message wrong and people die. That type of commitment to results is what Cemil brings to Risk Sciences International.

Full Bio...

Greg Paoli

As RSI’s Principal Risk Scientist and COO, Greg Paoli is currently working with a broad spectrum of clients in the public and private sectors, with the greatest emphasis on the development of new approaches to transform regulatory systems to be more “risk-based” at multiple levels: how senior decision-makers process risk information and make the “tough choices” in regulating health and safety, how an organization can optimize its resources across a diverse mandate to maximize total “portfolio-level” risk reduction, and how to operationalize key resources like the scheduling of inspections when faced with thousands of inspection targets, but not enough resources to inspect all of them.

Full Bio...

Nataliya Karyakina

Dr. Nataliya Karyakina has solid knowledge and extensive experience in hazard identification and human health risk assessments of toxic chemicals present in air, water, food and consumer products. Her research focuses on multidisciplinary studies of potential adverse health effects.

Full Bio...

Siva Ramoju

Siva Ramoju holds Masters Degrees in Biotechnology as well as Cellular Toxicology. His previous and present work in cellular toxicology has provided him with training and research experience in understanding how chemicals can damage individual cells, and an understanding of toxicity from the perspective of the whole animal.

Full Bio...

Michael G. Tyshenko

Dr. Tyshenko is involved with various health risk issues and is the lead on chemical peer reviews at RSI. He continues international research on infectious disease health policy and evidence-based decision-making for SARS, MERS and COVID-19 with a collaborative working group from China, USA, and the UAE. Other ongoing work in Nepal with the Ministry of Health in collaboration…

Full Bio...

Jennifer Go

Jennifer joined RSI in August of 2017 as a Risk Analyst with specialization in epidemiology. She possesses a diverse set of skills that contributes to her flexibility to work on a wide range of scientific projects. In particular, Jennifer has research experience in programming using SAS, manipulating large datasets, constructing statistical models, interpreting quantitative data, …

Full Bio...

Natalia (Natasha) Shilnikova

At RSI, Dr. Natalia (Natasha) Shilnikova has been working on projects involving toxicology, epidemiology and human health risk assessment, such as development of toxicity profiles for several chemicals on Health Canada’s Domestic Substances List (DSL); a systematic review of potential cancer and reproductive risks of artificial sweeteners for the International…

Full Bio...

Anne Wiles

For her work at RSI, Anne has built on her previous experience and academic research through work on communication on nuclear power and nuclear waste disposal; developing communication strategies and messaging on health risk issues; and delivering training on risk communication. She has also applied her familiarity with risk regulation in many projects on government…

Full Bio...